Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT01008462 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01008462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01008462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
March 18, 2010
Completion date
June 30, 2018
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell prolymphocytic leukemia, hypodiploidy, loss of chromosome 17p, plasma cell leukemia, progression of multiple myeloma or plasma cell leukemia, recurrent adult hodgkin lymphoma, recurrent adult non-hodgkin lymphoma, recurrent childhood hodgkin lymphoma, recurrent childhood non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent plasma cell myeloma, recurrent small lymphocytic lymphoma, refractory childhood hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory non-hodgkin lymphoma, refractory plasma cell myeloma, refractory small lymphocytic lymphoma, t(14;16), t(4;14), t-cell prolymphocytic leukemia, waldenstrom macroglobulinemia